So I went to the shrink. He was an important guy in a busy office, and the signs of his prestige were visible on numerous plaques on the walls. I had an hour with him and upon introducing himself I immediately felt uncomfortable, sensing his arrogance and over-confidence. He asked me to describe my situation and I didn’t feel at all comfortable sharing the intimate details of my life with him in our first visit. So, the time passed in an awkward sort of ping-pong exchange, where I felt defensive, and insisted of telling him about me, I insisted on knowing more about him.
Rafael Pharmaceutical’s first-in-class clinical lead compound, CPI-613, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies as a single agent, as well as in combination with standard drug therapies, in patients diagnosed with advanced solid tumors or blood cancers. The . Food and Drug Administration (FDA) has given Cornerstone approval to initiate pivotal clinical trials in pancreatic cancer and acute myeloid leukemia (AML), and has designated CPI-613 an orphan drug for the treatment of pancreatic cancer, AML, and myelodysplastic syndromes (MDS).
Industry Awards and Recognitions
March, 2016. Asklepion Pharmaceuticals, was awarded a 2016 Rare Impact Award by the National Organization for Rare Disorders (NORD).
January, 2016. Asklepion Pharmaceutical’s first product Cholbam® (cholic acid) is listed in the . Food and Drug Administration’s Novel Drug Summary for 2015.
Company About Us
Clinical Trials Overview
Acute Lung Injury Induced by CPB
Clinical Trial Sites